Back to Search Start Over

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology

Authors :
Lucy E Clark
Yulia Lomonosova
Amarjit Bhomra
Annemieke Aartsma-Rus
Anna M.L. Coenen-Stass
Margriet Hulsker
Tirsa L.E. van Westering
Thomas C. Roberts
Graham McClorey
Corinne A. Betts
Matthew J.A. Wood
Maaike van Putten
Source :
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 2, Pp 578-593 (2020), Journal of Cachexia, Sarcopenia and Muscle, 11(2), 578-593. WILEY, Journal of Cachexia, Sarcopenia and Muscle
Publication Year :
2019
Publisher :
WILEY, 2019.

Abstract

Background:Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disorder caused by genetic loss of dystrophin protein. Extracellular microRNAs (ex‐miRNAs) are putative, minimally invasive biomarkers of DMD. Specific ex‐miRNAs (e.g. miR‐1, miR‐133a, miR‐206, and miR‐483) are highly up‐regulated in the serum of DMD patients and dystrophic animal models and are restored to wild‐type levels following exon skipping‐mediated dystrophin rescue inmdxmice. As such, ex‐miRNAs are promising pharmacodynamic biomarkers of exon skipping efficacy. Here, we aimed to determine the degree to which ex‐miRNA levels reflect the underlying level of dystrophin protein expression in dystrophic muscle. Methods:Candidate ex‐miRNA biomarker levels were investigated inmdxmice in which dystrophin was restored with peptide‐PMO (PPMO) exon skipping conjugates and inmdx‐XistΔhsmice that express variable amounts of dystrophin from birth as a consequence of skewed X‐chromosome inactivation. miRNA profiling was performed inmdx‐XistΔhsmice using the FirePlex methodology and key results validated by small RNA TaqMan RT‐qPCR. The muscles from each animal model were further characterized by dystrophin western blot and immunofluorescence staining. Results:The restoration of ex‐myomiR abundance observed following PPMO treatment was not recapitulated in the high dystrophin‐expressingmdx‐XistΔhsgroup, despite these animals expressing similar amounts of total dystrophin protein (~37% of wild‐type levels). Instead, ex‐miRNAs were present at high levels inmdx‐XistΔhsmice regardless of dystrophin expression. PPMO‐treated muscles exhibited a uniform pattern of dystrophin localization and were devoid of regenerating fibres, whereasmdx‐XistΔhsmuscles showed non‐homogeneous dystrophin staining and sporadic regenerating foci. Conclusions:Uniform dystrophin expression is required to prevent ex‐miRNA release, stabilize myofiber turnover, and attenuate pathology in dystrophic muscle.

Details

Language :
English
Database :
OpenAIRE
Journal :
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 2, Pp 578-593 (2020), Journal of Cachexia, Sarcopenia and Muscle, 11(2), 578-593. WILEY, Journal of Cachexia, Sarcopenia and Muscle
Accession number :
edsair.doi.dedup.....bb13a752d993c0eb60ef9cbcd522405d